Lon­za swoops in with $1.2B to take over Roche’s bi­o­log­ics site in Cal­i­for­nia

With Lon­za an­tic­i­pat­ing per­sis­tent in­crease in de­mand for com­mer­cial bi­o­log­ics man­u­fac­tur­ing, the Swiss com­pa­ny is pick­ing up a pro­duc­tion site owned by Roche’s Genen­tech for $1.2 bil­lion in cash.

The man­u­fac­tur­er al­so has CHF 500 mil­lion ($562.5 mil­lion) in its bud­get to up­grade the Va­cav­ille, CA, fa­cil­i­ty to sup­port large-scale bi­o­log­ics pro­duc­tion for mam­malian drug sub­stances. The site has about 750 Genen­tech work­ers, who will be of­fered em­ploy­ment by the man­u­fac­tur­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER